Blood

Global Laboratory Glassware Washers Market Outlook & Forecast 2023-2028: A Shift from Manual to Automation in Laboratories - ResearchAndMarkets.com

Retrieved on: 
Monday, March 18, 2024
Research, Office Products, Home Goods, Biotechnology, Health, Pharmaceutical, Retail, Other Science, Science, Hospital, Automation, Quality control, Growth, Decontamination, University, Sterilization, Tissue, Laboratory, Health care, Urine, Drug development, Safety, Blood, Medical device

The global laboratory glassware washers market is expected to grow at a CAGR of 4.43% from 2022-2028.

Key Points: 
  • The global laboratory glassware washers market is expected to grow at a CAGR of 4.43% from 2022-2028.
  • The global laboratory glassware washers market is an evolving market landscape that caters to the diverse needs of scientific research, experimentation, and industrial processes.
  • The manual to laboratory automation shift has significantly impacted the laboratory glassware washers market.
  • Healthcare & clinical laboratories end-user segment accounted for the largest share of the global laboratory glassware washers market in 2022.

Paysign, Inc. to Sponsor the 2024 International Plasma Protein Congress April 16-17

Retrieved on: 
Thursday, March 14, 2024
Consulting, Data Management, Banking, Technology, Professional Services, Digital Cash Management, Digital Assets, Security, Research, Fintech, Science, Finance, Plasma, Congress, Blood, Patient, Safety, Therapy, Multimedia, PPTA

Paysign, Inc. (NASDAQ: PAYS ), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced their sponsorship and attendance of the International Plasma Protein Congress to be held April 16-17, 2024, in Athens, Greece.

Key Points: 
  • Paysign, Inc. (NASDAQ: PAYS ), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced their sponsorship and attendance of the International Plasma Protein Congress to be held April 16-17, 2024, in Athens, Greece.
  • View the full release here: https://www.businesswire.com/news/home/20240314923224/en/
    Paysign is proud to sponsor the 2024 International Plasma Protein Congress April 16-17 in Athens, Greece.
  • (Graphic: Business Wire)
    Paysign has been an associate member of the Plasma Protein Therapeutics Association (PPTA) and a sponsor of their conferences for over a decade.
  • The company proudly supports their global work to advocate for programs that ensure the quality and safety of plasma collection, manufacturing, patient access and advancements within the plasma ecosystem.

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Retrieved on: 
Friday, March 15, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, SLL, BMY, B-cell lymphoma, Chronic lymphocytic leukemia, CLL, Bone marrow, Caregiver, Patient, Lymphocytosis, City, CRS, Commercial, Bristol Myers Squibb, BTK, MRD, Cytokine release syndrome, Division, Drug resistance, Multimedia, Blood, Associate professor, Food, Pharmaceutical industry

Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Key Points: 
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
  • Please see the Important Safety Information section below, including Boxed WARNINGS for Breyanzi regarding Cytokine Release Syndrome (CRS), Neurologic Toxicities, and Secondary Hematological Malignancies.
  • “For years, attempts to bring other CAR T cell therapies to patients with relapsed or refractory CLL or SLL met challenges and found little success.
  • After relapsing or becoming refractory to these therapies, patients have few options and poor outcomes, including lack of durable complete responses.

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

Retrieved on: 
Wednesday, March 13, 2024
Neurology, Biotechnology, Pharmaceutical, Oncology, General Health, Health, FDA, Clinical Trials, Fast track (FDA), Psoriasis, Cell, Disease, Risk, Patient, Megakaryocyte, Immunoglobulin G, ITP, B cell, Quality of life, Platelet, Autoantibody, Gastrointestinal tract, CD38, Bleeding, Safety, Dravet syndrome, Blood, Lennox–Gastaut syndrome, Fatigue, Fiscal, Food, Autoimmune disease, Pharmaceutical industry

Takeda ( TSE:4502/NYSE:TAK ) today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP).

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP).
  • An interim analysis of the ongoing Phase 2 study demonstrated positive safety and efficacy results.
  • Based on these positive results, and following consultation with global health authorities, Takeda plans to initiate a global Phase 3 trial of mezagitamab in ITP in fiscal year 2024.
  • Results from the Phase 2 trial have no impact on the full year consolidated reported forecast for the fiscal year ending March 31, 2024 (Fiscal Year 2023).

Sunbird Bio to Present Findings From Study Assessing Key Alzheimer’s Disease Biomarker at the Tau2024 Global Conference

Retrieved on: 
Wednesday, March 13, 2024
Mental Health, Research, Neurology, Clinical Trials, Biotechnology, Health, General Health, Science, Oncology, Diagnosis, EV, Brain, Conference, Innovation, Disease, Alzheimer's disease, APEX, Protein, DSM-IV codes, Pathology, Therapy, Blood

“Utilizing our APEX diagnostic platform, we are continuing to expand our portfolio of blood-based tests in neurological disorders such as Alzheimer’s disease and Parkinson’s disease.

Key Points: 
  • “Utilizing our APEX diagnostic platform, we are continuing to expand our portfolio of blood-based tests in neurological disorders such as Alzheimer’s disease and Parkinson’s disease.
  • APEX, Sunbird Bio’s lead technology platform, is the first platform that directly detects EV-bound disease-specific proteins that aggregate in the brain.
  • Data to date have shown it is capable of detecting another key Alzheimer’s disease protein, amyloid beta, and other proteins associated with neurological disorders.
  • Following are details about the poster presentation at Tau2024:
    Presenter: Nicholas Ho, Ph.D., Head of Innovation and Scientific Co-Founder, Sunbird Bio

Pathway to Cures Announces First Entrepreneur in Residence

Retrieved on: 
Monday, March 11, 2024
Other Philanthropy, Biotechnology, Pharmaceutical, Health, Philanthropy, Fund Raising, Foundation, Other Health, Disease, Coagulopathy, Sickle cell disease, Heredity, Spark Therapeutics, Rush University Medical Center, Entrepreneur in residence, Knowledge, Mortality, Baxalta, EIR, Doctor of Philosophy, MD, MBA, Therapy, Anemia, Blood

Pathway to Cures (P2C) announced today its first Entrepreneur in Residence (EIR), Leonard Valentino, M.D.

Key Points: 
  • Pathway to Cures (P2C) announced today its first Entrepreneur in Residence (EIR), Leonard Valentino, M.D.
  • Dr. Valentino most recently served as President and CEO of the National Bleeding Disorders Foundation (NBDF) and was instrumental in bringing Pathway to Cures into reality.
  • Pathway to Cures is the venture philanthropy fund of the NBDF focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.
  • “My role as Entrepreneur in Residence for Pathway to Cures will be to provide guidance into the consideration and support of new opportunities for catalyzing transformative therapies and cures.

Inc. Business Media Announces the 2024 Female Founders List

Retrieved on: 
Thursday, April 4, 2024
Tears, Female, Lifting, Inc., Social media, Perspiration, Woman, Silicon, Fintech, Criterion, Silicon Valley Bank, Trailblazer, Blood

NEW YORK, April 4, 2024 /PRNewswire/ -- Inc. Business Media, known for discovering and spotlighting entrepreneurs making their mark on the world, will release its 2024 Female Founders list on April 9 on Inc.com and in the upcoming print issue available on April 16.

Key Points: 
  • NEW YORK, April 4, 2024 /PRNewswire/ -- Inc. Business Media, known for discovering and spotlighting entrepreneurs making their mark on the world, will release its 2024 Female Founders list on April 9 on Inc.com and in the upcoming print issue available on April 16.
  • The list, expanded to 250 names this year, highlights the resilient female founders whose achievements defied the conditions they faced such as keeping the internet running in war zones, coping with the collapse of Silicon Valley Bank, or facing personal crises.
  • "The female founders on this year's list are a testament to what triumph over adversity looks like.
  • The Female Founders 250 list was culled from thousands of entries through three rounds of judging—two internal and one by Inc.'s inaugural Female Founders advisers, looking specifically at an entrepreneur's bona fides in the past year.

FDA Approves New Antibiotic for Three Different Uses

Retrieved on: 
Wednesday, April 3, 2024
Daptomycin, Research, Hypersensitivity, Hypokalemia, Fungal infection, Aztreonam, Dizziness, Pneumonia, Survival, Dysgeusia, Potassium, Seizure, Abdominal pain, Dietary supplement, CABP, Headache, Patient, Public, Insomnia, Bacterial pneumonia, Food and Drug Administration, Animal, Bilirubin, Diarrhea, History, Mortality, Vancomycin, Leukopenia, Clostridioides, Human services, Injection site reaction, Nausea, Rash, Priority review, Bronchopneumonia, Skin, Fever, Heated tobacco product, Ceftriaxone, Safety, SAB, Anemia, Division, Phlebitis, Cosmetics, Vaccine, Infection, Food, Vomiting, Blood, Multimedia, FDA, Periodic breathing, ABSSSI, Pharmaceutical industry

"The FDA will continue our important work in this area as part of our efforts to protect the public health."

Key Points: 
  • "The FDA will continue our important work in this area as part of our efforts to protect the public health."
  • Zevtera's efficacy in treating SAB was evaluated in a randomized, controlled, double-blind, multinational, multicenter trial .
  • In the trial, researchers randomly assigned 390 subjects to receive Zevtera (192 subjects) or daptomycin plus optional aztreonam [the comparator] (198 subjects).
  • A total of 69.8% of subjects who received Zevtera achieved overall success compared to 68.7% of subjects who received the comparator.

Abbott Receives FDA Approval for TriClip™, First-of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve

Retrieved on: 
Tuesday, April 2, 2024
Disease, Atrial fibrillation, Risk, Anatomy, Patient, Aortic stenosis, Endoclip, Tricuspid regurgitation, Structural heart disease, Death, Tricuspid valve, Abbott Northwestern Hospital, Quality of life, Heart failure, Leg, Heart, MitraClip, Safety, Fatigue, Blood, FDA, Physician, Food, Pharmaceutical industry

The tricuspid valve controls blood as it flows from the heart's right atrium to the right ventricle.

Key Points: 
  • The tricuspid valve controls blood as it flows from the heart's right atrium to the right ventricle.
  • TR occurs when the valve doesn't close properly, causing a leak and allowing blood to flow backward in the heart.
  • TR can force the heart to work harder, causing debilitating symptoms such as fatigue and shortness of breath.
  • TriClip has been approved for use in more than 50 countries, including in Europe and Canada, since its initial CE Mark approval in 2020.

Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay

Retrieved on: 
Tuesday, April 2, 2024
Diagnosis, WGS, Disease, FACMG, Broad Institute, Genetic testing, Fragile X syndrome, Massachusetts General Hospital, MIT, Harvard University, CMA, Patient, Medical genetics, Research, Mortality, Laboratory, DGX, Senior, Genome, American College, Saliva, Intellectual disability, Hospital, Whole genome sequencing, ACMG, Blood, Quest Diagnostics, Antibiotics

SECAUCUS, N.J., April 2, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and Broad Clinical Labs, the world expert in whole genome sequencing (WGS), today announced a research collaboration designed to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.

Key Points: 
  • "We are delighted to bring the experience and expertise of Broad Clinical Labs to this innovative collaboration with Quest.
  • "This type of collaboration between commercial laboratories and research institutions is vital to advance the field of genetic testing and increase utility and economic value."
  • While the ACMG recommends WGS for first-line genetic testing for intellectual disability and developmental delay, some providers continue to follow prior guidelines that recommend chromosomal microarray (CMA) as a first-line test.
  • Broad Clinical Labs is a leader in human whole genome sequencing, having sequenced over 600,000 genomes in service of its mission to accelerate the understanding and diagnosis of human disease.